NEWS
- Pharma & Biotech News #PharmaBuzz
- Weekly News Recap #Phispers
- Recent Product Approvals #GreenLight
- Quality Compliance Alerts #Warning!
- All News #Library
DRUGS & DEVELOPMENTS
MARKET INTEL by PharmaCompass
Create content with us, ask us
By PharmaCompass
2018-10-18
Impressions: 110 Article
Generic versions of AbbVie’s Humira, the world’s biggest-selling drug, go on sale in Europe this week. However, in the US, Illinois-headquartered AbbVie has extended the drug’s shelf life by staving off Humira knockoffs to 2023. Humira is used to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis.
The deal this time is with Novartis’ generic arm, Sandoz, which has agreed to launch its biosimilar in the US later (in 2023) than other competitors. As per the current agreement, Amgen will launch its copycat version on January 31, 2023, Samsung Bioepis and Merck on June 30, 2023, Mylan on July 31, 2023, while Sandoz will launch it on September 30, 2023.
For AbbVie, the stakes are indeed high — last year, Humira brought in US$ 18 billion for the drug maker, and the sales are expected to increase by US$ 3 billion in 2020, driven by annual price hikes. On its part, AbbVie now has five years to get new drugs lined up to replace Humira.
In the EU though, Sandoz rolled out its biosimilar of Humira, branded as Amgevita, on October 16. Novartis said its Sandoz unit is launching its product Hyrimoz initially in Britain, with other markets set to follow.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
